Stockscreener 앱 받기
10.69
1.14%
0.12
시간 외 거래:
10.90
0.21
+1.96%
전일 마감가:
$10.57
열려 있는:
$10.92
하루 거래량:
324.83K
Relative Volume:
0.96
시가총액:
$3.63B
수익:
$804.63M
순이익/손실:
$-7.13M
주가수익비율:
-506.64
EPS:
-0.0211
순현금흐름:
$-73.42M
1주 성능:
-4.64%
1개월 성능:
-9.64%
6개월 성능:
-0.47%
1년 성능:
-1.57%
1일 변동 폭
$10.66
$10.94
1주일 범위
$10.43
$11.38
52주 변동 폭
$6.28
$13.11
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Compare TLX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
10.69 | 3.63B | 804.63M | -7.13M | -73.42M | -0.0211 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-17 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-18 | 개시 | Citigroup | Buy |
| 2025-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-03 | 개시 | H.C. Wainwright | Buy |
| 2025-06-05 | 개시 | Wedbush | Outperform |
| 2024-11-15 | 개시 | UBS | Buy |
모두보기
Telix Pharmaceuticals Ltd Adr 주식(TLX)의 최신 뉴스
Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth - GlobeNewswire Inc.
Kinzey Capital Management Signals Telix ITM Deal Impact - The Globe and Mail
Telix Director David Gill Boosts Nasdaq ADS Stake - The Globe and Mail
Telix Pharmaceuticals Director David Gill Acquires 11,800 ADS on Nasdaq - kalkine.com.au
Telix Pharmaceuticals Applies to Quote 1,645 Shares Issued Under Employee Stock Purchase Plan - kalkine.com.au
Telix announces acquisition of ITM to create a global radiopharmaceutical powerhouse - BiotechDispatch
Telix (TLX) lines up US$1.65B cancer drug merger—and a big revenue jump - Stock Titan
Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion - Yahoo! Finance Canada
Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion - finance.yahoo.com
Telix to acquire ITM in deal worth up to $2.35bn - Pharmaceutical Technology
Telix Strikes $1.65 Billion Deal to Acquire Germany's ITM, Building a Radiopharmaceutical Powerhouse - finance.biggo.com
Health Check: Telix strikes monster $3.3 billion merger deal to form radiopharma giant - Stockhead
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse - GlobeNewswire Inc.
Telix Pharmaceuticals to Merge with ITM Isotope Technologies Munich SE, Forming Advanced Radiopharmaceutical Leader - Kalkine Media
Telix Pharmaceuticals Announces Combination with ITM Isotope Technologies Munich SE - Kalkine
Telix Pharmaceuticals Applies to Quote 108,080 Shares Issued Under Employee Share Plans - Kalkine
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD - investing.com
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com Canada
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com UK
Two New York conferences will include Telix presentations - Stock Titan
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway - finance.yahoo.com
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com India
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Australia
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Canada
Telix Pharmaceuticals stock jumps on trial completion, FDA path - Investing.com
Up to 75% of prostate biopsies are negative. Telix enrolled 350 patients. - Stock Titan
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline - PR Newswire
Earnings call transcript: Telix H1 2026 profit jumps as guidance holds - Investing.com
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline - TradingView
Telix R&D Day to Feature Pipeline Updates and Outside Experts - Stock Titan
Telix Schedules Aug. 20 Webcast for Half-Year Results - Stock Titan
Study Tests Imaging to Select Patients for Telix Prostate Therapy - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21% - Kalkine
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
Telix Starts Phase 3 Targeted Radiation Study for Kidney Cancer - Stock Titan
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - Yahoo Finance
Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress - Investing.com
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Why Is Telix Pharmaceuticals (ASX:TLX) on Investors' Radar Despite a 30% One-Year Decline? - Kalkine
FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design - Stock Titan
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update - Kalkine
FDA Alignment to Advance ProstACT Global Phase 3 Trial - GlobeNewswire Inc.
Telix clears FDA protocol review for prostate cancer trial expansion - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals Ltd Adr (TLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Telix Pharmaceuticals Ltd Adr 주식 (TLX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Behrenbruch Christian | MD & Group CEO |
Apr 29 '26 |
Buy |
14.87 |
33,435 |
497,178 |
20,742,935 |
| Behrenbruch Christian | MD & Group CEO |
Apr 28 '26 |
Buy |
14.48 |
34,500 |
499,560 |
20,709,500 |
| Smith Darren Charlton | Group Chief Financial Officer |
Mar 29 '26 |
Option Exercise |
0.00 |
1,111 |
0 |
11,921 |
0.96%
자본화:
|
볼륨(24시간):